scholarly journals Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination

2021 ◽  
Author(s):  
Kelly M. Mahar ◽  
Stephen Caltabiano ◽  
Susan Andrews ◽  
Bandi Ramanjineyulu ◽  
Liangfu Chen ◽  
...  
Keyword(s):  
Clinical Pharmacokinetics ◽  
Excretion Study ◽  
Oral Doses

Determination of DP‐VPA and its active metabolite, VPA, in human plasma, urine, and feces by UPLC–MS/MS: A clinical pharmacokinetics and excretion study

2019 ◽  
Vol 11 (7) ◽  
pp. 1035-1047 ◽  
Author(s):  
Yi Li ◽  
Huizhong Zhan ◽  
Yaxin Fan ◽  
Jing Zhang ◽  
Guoying Cao ◽  
...  
Keyword(s):  
Human Plasma ◽  
Active Metabolite ◽  
Clinical Pharmacokinetics ◽  
Excretion Study

Clinical pharmacokinetics of procaterol: Dose proportionality after administration of single oral doses

1992 ◽  
Vol 13 (9) ◽  
pp. 663-669 ◽  
Author(s):  
Michael A. Eldon ◽  
Debbie S. Blake ◽  
Michael J. Coon ◽  
Gerald D. Nordblom ◽  
Allen J. Sedman ◽  
...  
Keyword(s):  
Dose Proportionality ◽  
Clinical Pharmacokinetics ◽  
Oral Doses

scholarly journals Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model

2018 ◽  
Vol 21 ◽  
pp. 236-246 ◽  
Author(s):  
Daniel Valente Neves ◽  
Carolina Pinto Vieira ◽  
Adriana Rocha ◽  
Vera Lucia Lanchote
Keyword(s):  
Human Subjects ◽  
Total Concentration ◽  
Cancer Resistance ◽  
Clinical Pharmacokinetics ◽  
Pharmacokinetic Drug Interaction ◽  
Coefficients Of Variation ◽  
Assay Precision ◽  
Therapeutic Doses ◽  
Oral Doses

PURPOSE: Ceftriaxone elimination occurs through breast cancer resistance transporter (BCRP) and multidrug resistance-associated protein 2 (MRP-2) which are expressed on the canalicular membrane of hepatocytes. Eltrombopag, a thrombopoetin receptor agonist used in the treatment of immune thrombocytopenic purpura, is reported in in vitro studies as an inhibitor of intestinal BCRP but not an inhibitor of hepatic BCRP. Thus, the present study evaluates the effect of therapeutic doses of eltrombopag on the clinical pharmacokinetics of intravenous ceftriaxone. METHODS: Healthy adult (n=12) were treated with oral doses of eltrombopag (0, 25 or 50 mg) 28 and 4 h prior to intravenous ceftriaxone administration (1g). Serial blood samples were collected up to 48 h after ceftriaxone administration and plasma samples were analysed by LC-MS/MS using 50 μL aliquots (total concentration) and 100 μL (unbound concentration). RESULTS: A method to analyze total and unbound ceftriaxone in plasma using LC-MS/MS was developed and validated with linearity from 1 to 200 μg/mL. Both methods are sensitive, precise and accurate with coefficients of variation less than 15% in the study of inter- and intra-assay precision and accuracy. Ceftriaxone pharmacokinetics in healthy adults were described using a bicompartmental model, with a mean clearance of 0.96 L/h (CI95% 0.71-1.20) and AUC0-∞of 1106 mg.h/mL (CI95% 811-1400) for volunteers that received only ceftriaxone; clearance of 0.95 L/h (CI95% 0.77-1.13) and AUC0-∞ of 1083 mg.h/mL (CI95% 876-1290) for volunteers that received ceftriaxone plus 25 mg of eltrombopag and clearance of 0.96 L/h (CI95% 0.74-1.19) and AUC0-∞ of 1072 mg.h/mL (CI95% 872-1273) for volunteers that received ceftriaxone plus 50 mg of eltrombopag. CONCLUSIONS: The results do not support the existence of a clinical pharmacokinetic drug interaction involving hepatic BCRP in human subjects receiving intravenous ceftriaxone and oral eltrombopag. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

Safety and Clinical Pharmacokinetics of Nemonoxacin, a Novel Non-Fluorinated Quinolone, in Healthy Chinese Volunteers Following Single and Multiple Oral Doses

2012 ◽  
Vol 32 (7) ◽  
pp. 475-486 ◽  
Author(s):  
Beining Guo ◽  
Xiaojie Wu ◽  
Yingyuan Zhang ◽  
Yaoguo Shi ◽  
Jicheng Yu ◽  
...  
Keyword(s):  
Clinical Pharmacokinetics ◽  
Healthy Chinese ◽  
Oral Doses

scholarly journals Excretion study of clomiphene in human urine: evaluation of endogenous steroids profile after multiple oral doses

2010 ◽  
Vol 21 (12) ◽  
pp. 2220-2225 ◽  
Author(s):  
Dayamín Martínez Brito ◽  
Rodny Montes de Oca Porto ◽  
Margarita Teresa Correa Vidal ◽  
Roberto Socarrás Ojeda ◽  
Arístides Rosado Pérez
Keyword(s):  
Human Urine ◽  
Excretion Study ◽  
Oral Doses ◽  
Endogenous Steroids

Methotrexate for psoriasis in weekly oral doses

1969 ◽  
Vol 99 (1) ◽  
pp. 86-93 ◽  
Author(s):  
H. H. Roenigk
Keyword(s):  
Oral Doses

Clinical Pharmacokinetics and Metabolism of Berberine and Hydrastine Following an Oral Dose of Goldenseal Supplement

Planta Medica ◽  
2010 ◽  
Vol 76 (05) ◽  
Author(s):  
PK Gupta ◽  
BJ Gurley ◽  
G Barone ◽  
HP Hendrickson
Keyword(s):  
Oral Dose ◽  
Clinical Pharmacokinetics
Sign in / Sign up

Export Citation Format

Share Document